Mirtazapine oral soluble film agent as well as preparation method and application thereof
By developing mirtazapine oral membrane solvent, micronization and surfactant to improve drug solubility, combined with flavoring agents and saliva stimulators, the poor palatability and local stimulation in cats are solved, rapid dissolution and efficient absorption are achieved, and the The dosing process and reduces the preparation cost.
Patent Information
- Application Number
- CN202310767443.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-06-27
- Publication Date
- 2024-12-03
AI Technical Summary
The existing mirtazapine agents have poor palatability, difficulty in administration and local stimulation reactions in cats, and the preparation of traditional lyophilized oral swelling tablets is cumbersome and costly, making it difficult to meet the needs of pet medical care.
Develop a mirtazapine oral film solvent containing mirtazapine, polymer film forming materials, surfactants, plasticizers, saliva stimulators and flavoring agents. Through micronization and the use of surfactants, the solubility of drugs can be improved. It is made of thin, fold-resistant and easy-to-carry oral-soluble film agents.
It significantly improves the administration compliance of cats, avoids local stimulation reactions, and rapidly dissolves and absorbs drugs in the oral cavity, reduces the first pass effect, improves bioavailability, and simplifies the transportation and storage process.
Smart Images

Figure BDA0004306811470000071 
Figure BDA0004306811470000081 
Figure BDA0004306811470000101
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of veterinary chemical preparations, and particularly relates to a mirtazapine orodispersible film-forming agent and a preparation method and application thereof. Background Art
[0002] Mirtazapine is a noradrenergic specific serotonergic antidepressant that works by antagonizing adrenergic α2-autoreceptors and α2-hetero-receptors and blocking 5-HT2 and 5-HT3 receptors. It is commonly used to treat depression and other mood disorders in humans. Mirtazapine is an effective appetite stimulant in cats or dogs and is used for nutritional support in dogs and cats with acute and chronic illnesses. Mirtazapine has antiemetic properties because it antagonizes 5-HT3 receptors and has been shown to reduce vomiting in cats with chronic kidney disease. A transdermal ointment containing mirtazapine is currently approved in the United States For weight gain in cats, the formulation is administered topically to the inside of the cat's ear pinna. The main side effect is local irritation to the cat's auricle, which is prone to erythema and rashes. In addition, cats' licking each other may lead to inaccurate dosage after local administration, reducing the efficacy of the drug. At present, traditional human mirtazapine drugs are still the main ones used in domestic pet medicine. However, in pet medical practice, when traditional human mirtazapine drugs are used, there is usually a problem of poor palatability, and pets resist taking the medicine, making it difficult to feed the medicine.
[0003] Orodispersible film is a drug-containing polymer film used to provide treatment in the mouth or through gastrointestinal absorption. As a new oral drug delivery dosage form, orodispersible film has the advantages of rapid dissolution in the mouth, thin thickness, light weight, folding and tensile resistance, easy to carry, and accurate dosage. It can overcome the shortcomings of orodisintegrating tablets that are fragile, poor folding resistance, and poor dosage control of oral liquid preparations. It can quickly release drugs and can promote some drugs to enter the systemic circulation system directly through the mucosa, avoiding the first-pass effect. In addition, orodispersible film can be well taste-masked by adding excipients such as sweeteners to increase palatability, thereby significantly improving the compliance of cats with drug administration.
[0004] Patent CN116077450A discloses a method for preparing a taste-masked orodisintegrating tablet of mirtazapine for cats by masking the taste with physical isolation. Patent CN108853042A discloses a method for preparing a freeze-dried orodisintegrating tablet of mirtazapine. Although freeze-dried orodisintegrating tablets are prepared by freeze-drying technology, the disintegration rate is accelerated and the dissolution is improved. However, freeze-drying technology is relatively cumbersome, the product cost is high, and the orodisintegrating tablet preparation has the disadvantages of large amount of auxiliary materials, high cost, low hardness, special packaging, inconvenient transportation and storage, and a sense of gravel after oral administration. In terms of application to improve the appetite of cats, the compliance of orodisintegrating tablets has a certain gap compared with orodisintegrating film preparations.
[0005] Therefore, it is necessary to develop an orosoluble film preparation of mirtazapine that has good palatability, good cat compliance, and is easy to transport and store. Summary of the invention
[0006] In view of the problems existing in the prior art, the present invention provides a mirtazapine orodispersible film preparation and a preparation method and application thereof. The orodispersible film has no irritating taste, can be quickly dissolved in the oral cavity, has a uniform drug content, has good tensile resistance, and improves cat compliance.
[0007] In one aspect, the present invention provides a mirtazapine orodispersible film preparation, comprising an active ingredient mirtazapine, a polymer film-forming material, a surfactant, a plasticizer, a saliva stimulant, and a flavor corrective.
[0008] The mass percentages of the components in the mirtazapine orodispersible film preparation are: 1% to 30% of mirtazapine, 40% to 60% of polymer film-forming material, 0% to 10% of surfactant, 0% to 20% of plasticizer, 0% to 10% of saliva stimulant and 0% to 15% of flavor corrective.
[0009] Preferably, the mass percentages of the components in the mirtazapine orodispersible film-forming agent are: 5% to 25% mirtazapine, 45% to 60% polymer film-forming material, 3% to 10% surfactant, 5% to 20% plasticizer, 2% to 8% saliva stimulant, and 5% to 13% flavoring agent.
[0010] More preferably, the mass percentages of the components in the mirtazapine orodispersible film-forming agent are: mirtazapine 8% to 15%, polymer film-forming material 48% to 56%, surfactant 5% to 10%, plasticizer 10% to 20%, saliva stimulant 3% to 7%, and flavoring agent 8% to 12%.
[0011] More preferably, the mass percentages of the components in the mirtazapine orodispersible film-forming agent are: 10% mirtazapine, 52% polymer film-forming material, 8% surfactant, 15% plasticizer, 5% saliva stimulant, and 10% flavoring agent.
[0012] The D90 particle size of the active ingredient mirtazapine in the mirtazapine oral film-dissolving preparation is 30 μm, preferably 20 μm, and more preferably 10 μm.
[0013] The polymer film-forming material in the mirtazapine oral film-dissolving agent is selected from one or more of hydroxypropyl methylcellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, polyethylene oxide, polyvinyl pyrrolidone, sodium carboxymethyl cellulose, polyvinyl alcohol, xanthan gum, gum arabic, and starch; preferably, the polymer film-forming material is hydroxypropyl methylcellulose.
[0014] The polymer film-forming material hydroxypropyl methylcellulose in the mirtazapine oral film-dissolving agent is selected from a material having a viscosity of <50 mPa·S when the solution concentration is 2% (W / V) at 20°C; preferably, the hydroxypropyl methylcellulose is selected from a material having a viscosity of 3-15 mPa·S when the solution concentration is 2% (W / V) at 20°C.
[0015] The surfactant in the mirtazapine orodispersible film is selected from one or more of poloxamer, sodium dodecyl sulfate, povidone, sodium dodecyl sulfate, Tween 20, Tween 80, sucrose ester, dodecyl maltoside, hexadecyltrimethylammonium bromide, dioctyl sodium sulfonate, Span 40, and Span 60; preferably, the surfactant is sodium dodecyl sulfate.
[0016] The present invention controls the particle size of the raw material drug, micronizes mirtazapine, and adds a surfactant to the prescription to increase the solubility of the poorly soluble raw material drug mirtazapine, which is beneficial to increasing the dissolution rate of the active ingredient in the oral cavity, so that the active ingredient can be quickly released and absorbed in the oral mucosa of the cat.
[0017] The plasticizer in the mirtazapine orodispersible film is selected from one or more of propylene glycol, glycerol, mannitol, polyethylene glycol, citric acid polyethylene glycol, and sorbitol; preferably, the plasticizer is propylene glycol.
[0018] The saliva stimulant in the mirtazapine oral film-dissolving agent is selected from one or more of citric acid, malic acid, tartaric acid, lactic acid and ascorbic acid; preferably, the saliva stimulant is citric acid.
[0019] The flavoring agent in the mirtazapine orodispersible film is selected from one or more of sucralose, glucose, sucrose, fructose, aspartame, maltose, mannitol, sodium steviol glycoside, sorbitol, xylitol, and cyclamate; preferably, the flavoring agent is sucralose.
[0020] The second aspect of the present invention provides a method for preparing a mirtazapine orodispersible film-forming agent, comprising the following steps:
[0021] (1) micronizing the mirtazapine API by grinding, sieving or airflow milling, and controlling the D90 particle size to be ≤30 μm, to obtain a micronized mirtazapine API;
[0022] (2) adding the polymer film-forming material, surfactant, plasticizer and other auxiliary materials to a portion of the hot purified water under stirring, stirring and dispersing them fully, then adding the remaining cold purified water to make the volume to the target volume, stirring and dispersing them fully to obtain a dispersed system;
[0023] (3) adding the micronized mirtazapine API obtained in step (1) to the dispersed system obtained in step (2) and stirring the mixture to obtain a mixed solution;
[0024] (4) allowing the mixed solution obtained in step (3) to stand overnight to remove any bubbles present in the mixed solution, thereby obtaining a drug-containing gel solution;
[0025] (5) coating, drying, and cutting the drug-containing glue obtained in step (4) to obtain the mirtazapine orodispersible film preparation.
[0026] The temperature of the hot purified water in step (2) is 0-90°C, preferably 50-90°C, more preferably 80°C.
[0027] The temperature of the cold purification in step (2) is 1-15°C, preferably 10-15°C.
[0028] The drying temperature in step (5) is 25-90°C, preferably 40-60°C, more preferably 50°C.
[0029] The third aspect of the present invention provides use of the mirtazapine orodispersible film-forming agent in the preparation of a medicament for improving the appetite of pets.
[0030] Preferably, the pet is a dog or a cat.
[0031] The invention prepares the mirtazapine orodispersible film preparation, uses a micronized raw material drug, adds a surfactant in the prescription to improve the drug solubility, adds a saliva stimulant and a flavor corrective to improve the palatability, thereby significantly improving the compliance of cats with drug administration.
[0032] Beneficial effects:
[0033] 1. The mirtazapine orodispersible film prepared by the present invention is thin, light, resistant to folding and pulling, and convenient to carry and transport. It has good palatability in improving cat appetite and can significantly improve cat compliance. Local irritation caused by the use of ointments can be avoided.
[0034] 2. The mirtazapine orodispersible film prepared by the present invention can dissolve quickly in the oral cavity and the drug can be dissolved quickly. This product uses micronized raw materials and the solubilization effect of surfactants to improve the solubility of the drug in the oral mucosa, thereby accelerating drug absorption, allowing the drug to directly enter the systemic circulation system, reducing the first-pass effect of the drug, and thus improving bioavailability. DETAILED DESCRIPTION
[0035] The above contents will be further described in detail below through specific implementation methods in the form of embodiments. However, this should not be understood as the scope of the above subject matter being limited to the following embodiments. All technologies realized based on the contents of the present invention are within the scope.
[0036] The mirtazapine API used in the embodiments of the present invention is the API crushed by air flow crusher without any explanation, and the D90 particle size is ≤10 μm. Of course, the D90 particle size can also be controlled to be ≤10 μm by grinding or sieving.
[0037] Example 1
[0038] A mirtazapine orodispersible film preparation, the ingredients and dosage of which are as follows:
[0039] Element Mass percentage 1000 tablets (2mg specification) prescription quantity / g Mirtazapine 10% 2 Hydroxypropyl methylcellulose E6 52% 10.4 Sodium Lauryl Sulfate 8% 1.6 Propylene glycol 15% 3 Citric acid monohydrate 5% 1 Sucralose 10% 2 <![CDATA[Purified water * > / 40ml
[0040] Note: *: used in the recipe but removed in the final product.
[0041] The preparation method of mirtazapine orodispersible film-dissolving agent comprises the following specific steps:
[0042] Add hydroxypropyl methylcellulose E6, sodium lauryl sulfate, propylene glycol, citric acid monohydrate and sucralose to 30 ml of 80°C purified water under stirring, stir and disperse thoroughly, then add the remaining 10 ml of 10°C purified water, stir thoroughly to completely dissolve the excipients, add micronized mirtazapine raw material under stirring, stir and disperse thoroughly to obtain a gel solution, then let it stand overnight to remove bubbles, use a coating machine to evenly coat the drug solution on a flat backing material PE film, dry at 50°C, and cut to obtain the mirtazapine orosoluble film-forming agent.
[0043] Example 2
[0044] A mirtazapine orodispersible film preparation, the ingredients and dosage of which are as follows:
[0045] Element Mass percentage 1000 tablets (2mg specification) prescription quantity / g Mirtazapine 10.5% 2 Hydroxypropyl methylcellulose E6 54.7% 10.4 Sodium Lauryl Sulfate 8.4% 1.6 glycerin 10.5% 2 Citric acid monohydrate 5.3% 1 Sucralose 10.5% 2 <![CDATA[Purified water * > / 40ml
[0046] Note: *: used in the recipe but removed in the final product.
[0047] The preparation method of mirtazapine orodispersible film-dissolving agent comprises the following specific steps:
[0048] Add hydroxypropyl methylcellulose E6, sodium lauryl sulfate, glycerol, citric acid monohydrate and sucralose to 30 ml of 80°C purified water under stirring, stir and disperse thoroughly, then add the remaining 10 ml of 10°C purified water, stir thoroughly to completely dissolve the excipients, add micronized mirtazapine raw material under stirring, stir and disperse thoroughly to obtain a gel solution, then let it stand overnight to remove bubbles, use a coating machine to evenly coat the drug solution on a flat backing material PE film, dry at 50°C, and cut to obtain the mirtazapine orosoluble film-forming agent.
[0049] Example 3
[0050] A mirtazapine orodispersible film preparation, the ingredients and dosage of which are as follows:
[0051] Element Mass percentage 1000 tablets (2mg specification) prescription quantity / g Mirtazapine 9.5% 2 Hydroxypropyl methylcellulose E6 49.5% 10.4 Sodium Lauryl Sulfate 7.6% 1.6 Polyethylene glycol 400 19% 4 Citric acid monohydrate 4.8% 1 Sucralose 9.5% 2 <![CDATA[Purified water * > / 40ml
[0052] Note: *: used in the recipe but removed in the final product.
[0053] The preparation method of mirtazapine orodispersible film-dissolving agent comprises the following specific steps:
[0054] Add hydroxypropyl methylcellulose E6, sodium lauryl sulfate, polyethylene glycol 400, citric acid monohydrate and sucralose to 30 ml of 80°C purified water under stirring, stir and disperse thoroughly, then add the remaining 10 ml of 10°C purified water, stir thoroughly to completely dissolve the excipients, add micronized mirtazapine raw material under stirring, stir and disperse thoroughly to obtain a gel solution, then let it stand overnight to remove bubbles, use a coating machine to evenly coat the drug solution on a flat backing material PE film, dry at 50°C, and cut to obtain the mirtazapine orosoluble film-forming agent.
[0055] Example 4
[0056] A mirtazapine orodispersible film preparation, the ingredients and dosage of which are as follows:
[0057] Element Mass percentage 1000 tablets (2mg specification) prescription quantity / g Mirtazapine 9.9% 2 Hydroxypropyl methylcellulose E6 51.5% 10.4 Sodium Lauryl Sulfate 7.9% 1.6 Propylene glycol 14.85% 3 Malic Acid 3.96% 0.8 sucrose 11.88% 2.4 <![CDATA[Purified water * > / 40ml
[0058] Note: *: used in the recipe but removed in the final product.
[0059] The preparation method of mirtazapine orodispersible film-dissolving agent comprises the following specific steps:
[0060] Hydroxypropyl methylcellulose E6, sodium lauryl sulfate, propylene glycol, malic acid and sucrose are added to 30 ml of 80°C purified water under stirring, and are fully stirred and dispersed. Then, the remaining 10 ml of 10°C purified water is added, and the auxiliary materials are fully stirred to completely dissolve. The micronized mirtazapine raw material is added under stirring, and is fully stirred and dispersed to obtain a gel solution. The gel solution is then allowed to stand overnight to remove bubbles. The drug solution is evenly coated on a flat backing material PE film using a coating machine, and the solution is dried at 50°C and cut to obtain the mirtazapine orosoluble film-forming agent.
[0061] Example 5
[0062] A mirtazapine orodispersible film preparation, the ingredients and dosage of which are as follows:
[0063] Element Mass percentage 1000 tablets (2mg specification) prescription quantity / g Mirtazapine 10.1% 2 Hydroxypropyl methylcellulose E6 52.5% 10.4 Sodium Lauryl Sulfate 8.1% 1.6 Propylene glycol 15.15% 3 tartaric acid 6.1% 1.2 glucose 8.1% 1.6 <![CDATA[Purified water * > / 40ml
[0064] Note: *: used in the recipe but removed in the final product.
[0065] The preparation method of mirtazapine orodispersible film-dissolving agent comprises the following specific steps:
[0066] Add hydroxypropyl methylcellulose E6, sodium lauryl sulfate, propylene glycol, tartaric acid and glucose into 30 ml of 80°C purified water under stirring, stir and disperse thoroughly, then add the remaining 10 ml of 10°C purified water, stir thoroughly to dissolve the excipients completely, add the micronized mirtazapine API under stirring, stir and disperse thoroughly to obtain a gel solution, then let it stand overnight to remove bubbles, use a coating machine to evenly coat the drug solution on a flat backing material PE film, dry at 50°C, and cut to obtain the mirtazapine orosoluble film-forming agent.
[0067] Example 6
[0068] A mirtazapine orodispersible film preparation, the ingredients and dosage of which are as follows:
[0069] Element Mass percentage 1000 tablets (2mg specification) prescription quantity / g Mirtazapine 10.2% 2 Hydroxypropyl methylcellulose E6 53.1% 10.4 Poloxamer 188 6.1% 1.2 Propylene glycol 15.3% 3 Citric acid monohydrate 5.1% 1 Sucralose 10.2% 2 <![CDATA[Purified water * > / 40ml
[0070] Note: *: used in the recipe but removed in the final product.
[0071] The preparation method of mirtazapine orodispersible film-dissolving agent comprises the following specific steps:
[0072] Hydroxypropyl methylcellulose E6, poloxamer 188, propylene glycol, citric acid monohydrate and sucralose are added to 30 ml of 80°C purified water under stirring, and are fully stirred and dispersed. Then, the remaining 10 ml of 10°C purified water is added, and the excipients are fully stirred to completely dissolve. The micronized mirtazapine bulk drug is added under stirring, and is fully stirred and dispersed to obtain a gel solution. The gel solution is then allowed to stand overnight to remove bubbles. The drug solution is evenly coated on a flat backing material PE film using a coating machine, and the solution is dried at 50°C and cut to obtain the mirtazapine orosoluble film-forming agent.
[0073] Example 7
[0074] A mirtazapine orodispersible film preparation, the ingredients and dosage of which are as follows:
[0075]
[0076]
[0077] Note: *: used in the recipe but removed in the final product.
[0078] The preparation method of mirtazapine orodispersible film-dissolving agent comprises the following specific steps:
[0079] Add hydroxypropyl methylcellulose E6, povidone K30, propylene glycol, citric acid monohydrate and sucralose to 30 ml of 80°C purified water under stirring, stir and disperse thoroughly, then add the remaining 10 ml of 10°C purified water, stir thoroughly to completely dissolve the excipients, add micronized mirtazapine raw material under stirring, stir and disperse thoroughly to obtain a gel solution, then let it stand overnight to remove bubbles, use a coating machine to evenly coat the drug solution on a flat backing material PE film, dry at 50°C, and cut to obtain the mirtazapine orosoluble film-forming agent.
[0080] Example 8
[0081] A mirtazapine orodispersible film preparation, the ingredients and dosage of which are as follows:
[0082] Element Mass percentage 1000 tablets (2mg specification) prescription quantity / g Mirtazapine 10% 2 Sodium Carboxymethyl Cellulose 52% 10.4 Sodium Lauryl Sulfate 8% 1.6 Propylene glycol 15% 3 Citric acid monohydrate 5% 1 Sucralose 10% 2 <![CDATA[Purified water * > / 40ml
[0083] Note: *: used in the recipe but removed in the final product.
[0084] The preparation method of mirtazapine orodispersible film-dissolving agent comprises the following specific steps:
[0085] Sodium carboxymethyl cellulose, sodium dodecyl sulfate, propylene glycol, citric acid monohydrate and sucralose are added to 30 ml of 80°C purified water under stirring, and are fully stirred and dispersed. Then, the remaining 10 ml of 10°C purified water is added, and the mixture is fully stirred to completely dissolve the excipients. The micronized mirtazapine bulk drug is added under stirring, and the mixture is fully stirred and dispersed to obtain a gel solution. The gel solution is then allowed to stand overnight to remove bubbles. A coating machine is used to evenly coat the drug solution on a flat backing material PE film, and the solution is dried at 50°C and cut to obtain a mirtazapine orosoluble film-dissolving agent.
[0086] Comparative Example 1
[0087] A mirtazapine orodispersible film-forming agent, wherein the raw material drug is a raw material drug that has not been airflow-crushed, and the D90 particle size is 60 μm, and is prepared by the following method:
[0088] Element Mass percentage 1000 tablets (2mg specification) prescription quantity / g Mirtazapine (non-micronized) 10% 2 Hydroxypropyl methylcellulose E6 52% 10.4 Sodium Lauryl Sulfate 8% 1.6 Propylene glycol 15% 3 Citric acid monohydrate 5% 1 Sucralose 10% 2 <![CDATA[Purified water * > / 40ml
[0089] Note: *: used in the recipe but removed in the final product.
[0090] The preparation method of mirtazapine orodispersible film-dissolving agent comprises the following specific steps:
[0091] Hydroxypropyl methylcellulose E6, sodium lauryl sulfate, propylene glycol, citric acid monohydrate and sucralose are added to 30 ml of 80°C purified water under stirring, and are fully stirred and dispersed. Then, the remaining 10 ml of 10°C purified water is added, and the mixture is fully stirred to completely dissolve the excipients. Mirtazapine (not micronized) is added under stirring, and is fully stirred and dispersed to obtain a gel solution. The gel solution is then allowed to stand overnight to remove bubbles. A coating machine is used to evenly coat the drug solution on a flat backing material PE film, and the solution is dried at 50°C and cut to obtain a mirtazapine orosoluble film-dispersible preparation.
[0092] Example 9 Mechanical Properties
[0093] Plasticizers mainly affect the elongation, tensile strength and plasticity of the orodissolving film. The mechanical properties of the orodissolving films of Example 1, Example 2 and Example 3 with different plasticizers were tested using a Labthink XLW (EC) intelligent electronic tensile testing machine, and the testing machine was operated at a speed of 50 mm / min. The results are shown in the table below.
[0094] Table 1 Mechanical properties of different plasticizers
[0095] Example Thickness(μm) <![CDATA[Tensile strength (N / mm 2 )]]> 1 90 13.1 2 100 9.5 3 90 9.2
[0096] From the above data, it can be seen that the mirtazapine oral film-dissolving agent prepared in Example 1 uses propylene glycol as a plasticizer, and the tensile strength is greater than 10N / mm 2 It has certain folding resistance and tensile strength, which can ensure the integrity of the product during transportation, storage and use. The tensile strength is significantly better than that of the preparations in Example 2 (the plasticizer is glycerol) and Example 3 (the plasticizer is polyethylene glycol 400).
[0097] Example 10 Evaluation of drug irritation taste
[0098] The orodispersible films of Example 1, Example 4, Example 5 and Comparative Example 1 were tasted and scored. The scoring results are shown in the following table.
[0099] Table 2 Taste comparison results
[0100] Example 1 4 5 Comparative Example 1 Bitterness score of orally dissolving film 0 3 5 0 Taste No grit No grit No grit Gritty
[0101] Note: The standard for evaluating irritation is 0: no irritation, 1: minimal irritation, 2: slight irritation, 3: strong irritation, 4: strong irritation, 5: unbearable irritation.
[0102] From the above data, it can be seen that the mirtazapine orodispersible film prepared with the salivary stimulant citric acid monohydrate and the flavor corrector sucralose used in Example 1 has no irritating taste, and compared with the mirtazapine orodispersible film prepared without airflow powdering of the raw material, there is no gritty feeling in the mouth.
[0103] Example 11 Melting Time Investigation
[0104] Dissolution time is an important quality indicator of orally dissolving films. The speed at which a drug dissolves in the mouth will affect the drug's clinical compliance and absorption adequacy. According to the general requirements for oral preparations and films in Part II of the 2020 edition of the Chinese Pharmacopoeia, the dissolution time of the film product of the present invention is limited to <60 seconds.
[0105] Randomly select 6 pieces of dissolving agents from the above 8 embodiments and comparative examples to measure their dissolution time, and calculate the average dissolution time. Clamp them with two layers of stainless steel mesh with an inner diameter of 2.0 mm, immerse them in a 100 ml beaker, and the cup contains about 50 ml of water at a temperature of 37°C ± 1°C. Adjust the height of the stainless steel mesh so that the lower surface is not less than 10 mm from the bottom of the beaker, and the upper surface of the stainless steel mesh is submerged in the water. Place the beaker in an oscillator with an oscillation frequency of 30 times per minute. Observe and record the time it takes for the product to completely dissolve and pass through the mesh, and record it in the table below.
[0106] Table 3 Melting time limit inspection table
[0107]
[0108] From the above data, it can be seen that the use of hydroxypropyl methylcellulose as a film-forming material and propylene glycol as a plasticizer has an outstanding dissolution effect, and the obtained film quickly dissolves in water to release the drug. The dissolution time is significantly better than that of the preparations of Example 8 (the film-forming material is sodium carboxymethyl cellulose), Example 2 (the plasticizer is glycerol), and Example 3 (the plasticizer is polyethylene glycol 400).
[0109] Example 12 In vitro dissolution study
[0110] In vitro dissolution experiments were carried out on homemade samples and marketed orally disintegrating tablets. The experimental results are shown in the table below.
[0111] Table 4 In vitro dissolution test table
[0112]
[0113] From the above data, it can be seen that the mirtazapine orodispersible film prepared by the present invention can release faster than the marketed orodispersible tablets regardless of whether the particle size of the raw material drug is subjected to airflow crushing. The release rate of the raw material drug after airflow crushing is more obvious, and the dissolution rate in 6 minutes is ≥84%.
[0114] Example 13 Palatability Evaluation
[0115] Example 1 and the orodisintegrating tablets on the market were subjected to a palatability test. 20 healthy Chinese rural cats were selected and randomly divided into 2 groups, with 10 cats in each group; the orodisintegrating film of Example 1 and the orodisintegrating tablets on the market were administered respectively to observe the reactions of the animals. The results are shown in the following table:
[0116] Table 5 Palatability of cats
[0117] Cat Behavior Example 1 (N=20) Orally disintegrating tablets (N=20) Cat licking mouth normally 16 8 Cats secrete more saliva 16 7 Cats shake their heads and resist 0 5 Acceptability / palatability 80% 40%
[0118] The test results show that 80% of cats can accept the palatability of the orodisintegrating film of Example 1. However, 40% of cats can accept the palatability of the orodisintegrating tablets on the market. This indicates that the palatability of the orodisintegrating film of mirtazapine is significantly improved compared with the orodisintegrating tablets.
[0119] Example 14 Pharmacokinetics
[0120] 24 healthy Chinese rural cats weighing 2-8 kg were selected and randomly divided into two treatment groups (12 in each group) in a double-treatment, double-period, crossover design, with an 8-day washout period between the two treatment groups. The fasting cats were given the product of Example 1 and the marketed orally disintegrating tablets according to their body weight, and blood samples of 2 ml were drawn at 0, 0.5, 1, 1.5, 2, 4, 6, 12, 24, 36, and 48 hours after administration for testing. The results are as follows:
[0121] Table 6 Pharmacokinetic test results
[0122]
[0123]
[0124] The above results show that mirtazapine orodispersible film-forming agent has a more rapid onset of action and can improve its bioavailability in cats compared with the marketed orodispersible tablets.
Claims
1. A mirtazapine orodispersible film-forming agent, characterized in that: The orodispersible film comprises an active ingredient, mirtazapine, a polymer film-forming material, a surfactant, a plasticizer, a saliva stimulant and a flavor corrective.
2. The mirtazapine orosoluble film preparation according to claim 1, characterized in that: The mass percentages of the components in the orodispersible film preparation are: 1% to 30% of mirtazapine, 40% to 60% of polymer film-forming material, 0% to 10% of surfactant, 0% to 20% of plasticizer, 0% to 10% of saliva stimulant, and 0% to 15% of flavor corrective.
3. The mirtazapine orosoluble film preparation according to claim 2, characterized in that: The mass percentages of the components in the orodispersible film preparation are: 5% to 25% of mirtazapine, 45% to 60% of polymer film-forming material, 3% to 10% of surfactant, 5% to 20% of plasticizer, 2% to 8% of saliva stimulant and 5% to 13% of flavor corrective.
4. The mirtazapine orosoluble film preparation according to any one of claims 1 to 3, characterized in that: The polymer film-forming material in the mirtazapine orosoluble film preparation is one or more of hydroxypropyl methylcellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, polyoxyethylene, polyvinyl pyrrolidone, sodium carboxymethyl cellulose, polyvinyl alcohol, xanthan gum, gum arabic, and starch; the plasticizer in the mirtazapine orosoluble film preparation is one or more of propylene glycol, glycerol, mannitol, polyethylene glycol, citric acid polyethylene glycol, and sorbitol.
5. The mirtazapine orosoluble film preparation according to claim 4, characterized in that: The polymer film-forming material in the mirtazapine orosoluble film preparation is hydroxypropyl methylcellulose; and the plasticizer is propylene glycol.
6. The mirtazapine orosoluble film preparation according to any one of claims 1 to 3, characterized in that: The surfactant in the mirtazapine orosoluble film preparation is selected from one or more of poloxamer, sodium lauryl sulfate, povidone, sodium lauryl sulfate, Tween 20, Tween 80, sucrose ester, dodecyl maltoside, hexadecyltrimethylammonium bromide, dioctyl sodium thiosulfonate, Span 40, and Span 60.
7. The mirtazapine orosoluble film preparation according to claim 6, characterized in that: The surfactant in the mirtazapine orosoluble film preparation is sodium lauryl sulfate.
8. The mirtazapine orosoluble film preparation according to any one of claims 1 to 3, characterized in that: The saliva stimulant in the mirtazapine orodispersible film preparation is selected from one or more of citric acid, malic acid, tartaric acid, lactic acid, and ascorbic acid; the flavoring agent in the mirtazapine orodispersible film preparation is selected from one or more of sucralose, glucose, sucrose, fructose, aspartame, maltose, mannitol, sodium steviol glycoside, sorbitol, xylitol, and cyclamate.
9. A method for preparing a mirtazapine orodispersible film-dispersible preparation as claimed in any one of claims 1 to 8, comprising the following steps: (1) micronizing the mirtazapine API by grinding, sieving or airflow milling, and controlling the D90 particle size to be ≤30 μm, to obtain a micronized mirtazapine API; (2) adding the polymer film-forming material, surfactant, plasticizer and other auxiliary materials to a portion of hot purified water under stirring, stirring and dispersing them fully, adding the remaining purified water to make the volume to the target volume, stirring them fully and evenly to obtain a dispersed system; (3) adding the crushed mirtazapine bulk drug obtained in step (1) to the dispersed system obtained in step (2) and stirring uniformly to obtain a mixed solution; (4) allowing the mixed solution obtained in step (3) to stand overnight to remove any bubbles present in the mixed solution, thereby obtaining a drug-containing gel solution; (5) coating, drying and cutting the drug-containing glue obtained in step (4).
10. Use of the mirtazapine orodispersible film-forming agent according to any one of claims 1 to 8 in the preparation of a medicament for improving the appetite of pets.
Citation Information
Patent Citations
Mirtazapine freeze-drying oral disintegrating tablet and preparation method thereof
CN108853042A
Miltazapine taste-masking orally disintegrating tablet as well as preparation method and application thereof
CN116077450A
